Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations
13 Oct 2022 //
ACCESSWIRE
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
16 Aug 2022 //
ACCESSWIRE
FDA Approves & Grants ODD to Aytu`s Enzastaurin in VEDS
14 Dec 2021 //
PRNEWSWIRE
First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102
08 Jan 2021 //
PRNEWSWIRE
Enterprise Therapeutics Awarded up to £5.7M from Cystic Fibrosis Foundation
16 Oct 2019 //
BUSINESSWIRE
First Patient Dosed In Pivotal Phase 3 Study Of First Line Therapy for DLBCL
03 Apr 2018 //
PR NEWSWIRE